PURPOSE: The capability of the electrostatic next generation impactor (eNGI) has been investigated as a tool capable of measuring the electrostatic charge of single (Flixotide; containing fluticasone propionate (FP)) and combination (Seretide; FP and salmeterol xinafoate (SX)) pressurised metered dose inhalers (pMDIs) at different flow rates. METHODS: Aerosol mass distributions were investigated at 30, 60 and 90 l.min(-1) and simultaneous charge measurements recorded. RESULTS: Analysis of the mass distribution data indicated a flow dependent relationship, where the aerosol performance (aerodynamic diameter <5 mum) of FP significantly increased between 30 l.min(-1) and 60 l.min(-1) for both formulations. No significant increase in SX was observed for Seretide with increased flow rate. Analysis of the charge distribution indicated both formulations to primarily charge negatively with a concurrent increase in charge with increased flow rate. Interestingly, the charge-tomass ratio remained relatively constant between 30 l.min(-1) and 60 l.min(-1) and increased at 90 l.min(-1), indicating that charging was majorly influenced at the highest flow rate. CONCLUSIONS: This study has shown how the eNGI could be used as a simple Pharmacopeia based methodology for the evaluation of mass and charge profiles of single and combination pMDIs at a series of flow rates.
PURPOSE: The capability of the electrostatic next generation impactor (eNGI) has been investigated as a tool capable of measuring the electrostatic charge of single (Flixotide; containing fluticasone propionate (FP)) and combination (Seretide; FP and salmeterol xinafoate (SX)) pressurised metered dose inhalers (pMDIs) at different flow rates. METHODS: Aerosol mass distributions were investigated at 30, 60 and 90 l.min(-1) and simultaneous charge measurements recorded. RESULTS: Analysis of the mass distribution data indicated a flow dependent relationship, where the aerosol performance (aerodynamic diameter <5 mum) of FP significantly increased between 30 l.min(-1) and 60 l.min(-1) for both formulations. No significant increase in SX was observed for Seretide with increased flow rate. Analysis of the charge distribution indicated both formulations to primarily charge negatively with a concurrent increase in charge with increased flow rate. Interestingly, the charge-tomass ratio remained relatively constant between 30 l.min(-1) and 60 l.min(-1) and increased at 90 l.min(-1), indicating that charging was majorly influenced at the highest flow rate. CONCLUSIONS: This study has shown how the eNGI could be used as a simple Pharmacopeia based methodology for the evaluation of mass and charge profiles of single and combination pMDIs at a series of flow rates.
Authors: Virgil A Marple; Daryl L Roberts; Francisco J Romay; Nicholas C Miller; Keith G Truman; Michiel Van Oort; Bo Olsson; Michael J Holroyd; Jolyon P Mitchell; Dieter Hochrainer Journal: J Aerosol Med Date: 2003
Authors: Virgil A Marple; Bernard A Olson; Kumaragovindham Santhanakrishnan; Jolyon P Mitchell; Sharon C Murray; Buffy L Hudson-Curtis Journal: J Aerosol Med Date: 2003
Authors: Martin Rowland; Alessandro Cavecchi; Frank Thielmann; Janusz Kulon; Jag Shur; Robert Price Journal: Pharm Res Date: 2018-11-26 Impact factor: 4.200
Authors: Yang Chen; Paul M Young; David F Fletcher; Hak Kim Chan; Edward Long; David Lewis; Tanya Church; Daniela Traini Journal: Pharm Res Date: 2014-10-01 Impact factor: 4.200
Authors: Yang Chen; Paul M Young; David F Fletcher; Hak Kim Chan; Edward Long; David Lewis; Tanya Church; Daniela Traini Journal: Pharm Res Date: 2013-12-03 Impact factor: 4.200
Authors: Yongquan Li; Adam Bohr; Henrik Jensen; Jukka Rantanen; Claus Cornett; Moritz Beck-Broichsitter; Johan Peter Bøtker Journal: Pharm Res Date: 2020-01-21 Impact factor: 4.200
Authors: Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid Journal: J Aerosol Med Pulm Drug Deliv Date: 2016-02-01 Impact factor: 2.849